ALLO
Allogene Therapeutics Inc.
$1.24
+$0.03(+2.48%)
38
Overall
60
Value
27
Tech
28
Quality
Market Cap
$253.73M
Volume
1.65M
52W Range
$0.86 - $3.78
Target Price
$7.56
Order:
Income Statement
| Metric | Trend | Chart | 2018 Dec | 2019 Dec | 2020 Dec | 2021 Dec | 2022 Dec | 2023 Dec | 2024 Dec |
|---|---|---|---|---|---|---|---|---|---|
| REVENUE | |||||||||
| Total Revenue | -- | -- | -- | $38.5M | $156.0K | $95.0K | $22.0K | ||
| Total Revenue | -- | -- | -- | $38.5M | $156.0K | $95.0K | $22.0K | ||
| GROSS PROFIT | |||||||||
| Gross Profit | -- | -- | -- | $38.5M | $156.0K | $95.0K | $22.0K | ||
| OPERATING EXPENSES | |||||||||
| Operating Expenses | $-192.8M | $202.0M | $258.2M | $294.3M | $335.7M | $327.8M | $273.2M | ||
| Research & Development | $151.9M | $144.5M | $193.0M | $220.2M | $256.4M | $242.9M | $192.3M | ||
| Research Expense | $151.9M | $144.5M | $193.0M | $220.2M | $256.4M | $242.9M | $192.3M | ||
| Selling, General & Administrative | $41.0M | $57.5M | $65.3M | $74.1M | $79.3M | $71.7M | $65.2M | ||
| General & Administrative Expenses | $41.0M | $57.5M | $65.3M | $74.1M | $79.3M | $71.7M | $65.2M | ||
| Salaries & Wages | $-18.6M | $59.5M | $59.5M | -- | -- | $66.0M | $51.7M | ||
| Depreciation & Amortization | $-1.0M | $4.6M | $7.4M | $10.5M | $14.3M | $14.2M | $13.6M | ||
| Depreciation & Amortization | $-1.0M | $4.6M | $7.4M | $10.5M | $14.3M | $14.2M | $13.6M | ||
| Amortization | $-452.0K | $603.0K | -- | -- | -- | -- | -- | ||
| Other Operating Expenses | $-920.0K | $268.0K | $1.1M | $-3.6M | $-4.8M | $-4.3M | $-3.1M | ||
| OPERATING INCOME | |||||||||
| Operating income | $-192.8M | $-202.0M | $-258.2M | $-255.8M | $-335.5M | $-327.7M | $-273.2M | ||
| EBITDA | $-203.4M | $-179.9M | $-250.7M | $-169.7M | $-321.2M | $-334.7M | $-243.5M | ||
| NON-OPERATING ITEMS | |||||||||
| Interest Expense (Non-Operating) | $3.4M | -- | -- | -- | -- | -- | -- | ||
| Intinc | $-21.2M | -- | -- | $1.7M | $4.6M | $18.3M | $20.2M | ||
| Net Non-Operating Interest Income/Expense | $-24.6M | -- | -- | $1.7M | $4.6M | $18.3M | $20.2M | ||
| Other Income/Expense | $-5.8M | $-17.4M | $-9.2M | $2.9M | $-9.4M | $31.0M | $19.6M | ||
| Other Special Charges | $5.8M | $17.4M | $9.2M | $-2.9M | $-9.4M | $-17.8M | $-3.9M | ||
| SPECIAL ITEMS | |||||||||
| Restructring And Mn A Income | -- | -- | $-1.0B | $-525.6M | $-248.1M | $-438.6M | $-361.5M | ||
| Special Income Charges | -- | -- | $1.0B | $525.6M | $248.1M | $438.6M | $361.5M | ||
| Other Impairment Of Capital Assets | -- | -- | -- | -- | -- | $13.2M | $15.7M | ||
| PRE-TAX INCOME | |||||||||
| EBIT | $-208.3M | $-184.9M | $-258.2M | $-180.2M | $-335.5M | $-348.9M | $-257.1M | ||
| Pre-Tax Income | $-211.6M | $-184.9M | $-250.2M | $-257.0M | $-340.4M | $-327.3M | $-257.1M | ||
| INCOME TAX | |||||||||
| Tax Provision | $-117.0K | $-331.0K | $-18.7M | $-692.0K | $-40.6M | $-21.6M | $443.0K | ||
| NET INCOME | |||||||||
| Net Income | $-211.5M | $-184.6M | $-316.4M | $-182.1M | $-340.4M | $-327.3M | $-257.6M | ||
| Net Income (Continuing Operations) | $-211.5M | $-184.6M | $-250.2M | $-257.0M | $-340.4M | $-327.3M | $-257.6M | ||
| Net Income (Discontinued Operations) | $-211.5M | $-184.6M | $-316.4M | $-182.1M | $-340.4M | $-327.3M | $-257.6M | ||
| Net Income (Common Stockholders) | $-211.5M | $-184.6M | $-316.4M | $-182.1M | $-340.4M | $-327.3M | $-257.6M | ||
| Normalized Income | -- | -- | -- | -- | -- | -- | $-600.7M | ||
| TOTALS | |||||||||
| Total Expenses | $-192.8M | $202.0M | $258.2M | $294.3M | $335.7M | $327.8M | $273.2M | ||
| SHARE & EPS DATA | |||||||||
| Average Shares Outstanding | $28.9M | $101.1M | $120.4M | $135.8M | $143.1M | $156.9M | $194.8M | ||
| Average Shares Outstanding (Diluted) | $28.9M | $101.1M | $120.4M | $135.8M | $143.1M | $156.9M | $194.8M | ||
| Shares Outstanding | $121.5M | $124.9M | $140.6M | $142.8M | $144.5M | $169.1M | $217.3M | ||
| Basic EPS | -- | $-1.83 | $-2.08 | $-1.89 | $-2.32 | $-2.09 | $-1.32 | ||
| Basic EPS (Continuing Operations) | -- | $-1.83 | $-2.08 | $-1.89 | $-2.32 | $-2.09 | $-1.32 | ||
| Diluted EPS | $-7.31 | $-1.83 | $-2.08 | $-1.89 | $-2.32 | $-2.09 | $-1.32 | ||
| Diluted EPS (Continuing Operations) | -- | -- | -- | $-1.89 | $-2.32 | $-2.09 | $-1.32 | ||
| OTHER METRICS | |||||||||
| Gain On Sale Of P P E | -- | $200.0K | -- | $100.0K | $100.0K | $100.0K | $300.0K | ||
| Other Gand A | $41.0M | $57.5M | $65.3M | $74.1M | $79.3M | $71.7M | $65.2M | ||
| Rent And Landing Fees | $41.0M | $5.9M | -- | -- | -- | -- | -- | ||
| Restruct | -- | -- | $-1.0B | $-525.6M | $-248.1M | $-438.6M | $-361.5M | ||
Financial data is updated quarterly and may not reflect the most recent earnings.
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | ALLO | $1.24 | +2.5% | 1.65M |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Allogene Therapeutics Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW